Clinical Trial Update: Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of CB-839 (telaglenastat) in combination with talazoparib in solid tumors was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Solid Tumor

Drugs mentioned

• CB-839 (telaglenastat)
• Talazoparib (talazoparib)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-02-17